Candel Therapeutics, Inc. (NASDAQ: CADL) is a Healthcare company (Biotechnology) with a market capitalization of $456M. The Maz Rating grades it against the other companies in its sector.
Candel Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.81, Candel Therapeutics, Inc. trades at 3.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -88.6%, return on invested capital of -44.4% and a free cash flow yield of -14.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.57. Over the past 52 weeks the share price ranged from $4.35 to $14.00, with a beta of -0.47.
Candel Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.